Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTL NASDAQ:CGEM NASDAQ:DNTH NASDAQ:FTLF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.68-2.3%$1.62$1.11▼$5.00$447.12M1.842.37 million shs2.64 million shsCGEMCullinan Therapeutics$8.74+1.3%$6.93$5.68▼$17.90$516.27M-0.12534,889 shs1.63 million shsDNTHDianthus Therapeutics$36.00-0.6%$30.41$13.36▼$40.16$1.16B1.58427,658 shs465,640 shsFTLFFitLife Brands$18.69-6.7%$18.43$9.83▼$20.98$175.52M0.6519,281 shs20,330 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics+6.17%-2.27%+30.30%-28.93%-59.62%CGEMCullinan Therapeutics+11.50%+33.80%+35.91%+11.07%-46.86%DNTHDianthus Therapeutics+1.86%+4.17%-2.27%+77.89%+31.45%FTLFFitLife Brands-0.10%-3.52%+9.99%+51.06%+25.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.68-2.3%$1.62$1.11▼$5.00$447.12M1.842.37 million shs2.64 million shsCGEMCullinan Therapeutics$8.74+1.3%$6.93$5.68▼$17.90$516.27M-0.12534,889 shs1.63 million shsDNTHDianthus Therapeutics$36.00-0.6%$30.41$13.36▼$40.16$1.16B1.58427,658 shs465,640 shsFTLFFitLife Brands$18.69-6.7%$18.43$9.83▼$20.98$175.52M0.6519,281 shs20,330 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics+6.17%-2.27%+30.30%-28.93%-59.62%CGEMCullinan Therapeutics+11.50%+33.80%+35.91%+11.07%-46.86%DNTHDianthus Therapeutics+1.86%+4.17%-2.27%+77.89%+31.45%FTLFFitLife Brands-0.10%-3.52%+9.99%+51.06%+25.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 2.71Moderate Buy$9.12442.86% UpsideCGEMCullinan Therapeutics 2.57Moderate Buy$26.00197.48% UpsideDNTHDianthus Therapeutics 2.82Moderate Buy$60.8869.10% UpsideFTLFFitLife Brands 3.00Buy$23.0023.06% UpsideCurrent Analyst Ratings BreakdownLatest FTLF, CGEM, DNTH, and AUTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025DNTHDianthus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$56.0010/8/2025AUTLAutolus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CGEMCullinan TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025DNTHDianthus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025FTLFFitLife BrandsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)10/6/2025FTLFFitLife BrandsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/27/2025AUTLAutolus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CGEMCullinan TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025DNTHDianthus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025FTLFFitLife BrandsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)9/24/2025AUTLAutolus TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$29.93M14.94N/AN/A$1.61 per share1.04CGEMCullinan TherapeuticsN/AN/AN/AN/A$10.14 per shareN/ADNTHDianthus Therapeutics$4.85M238.72N/AN/A$11.91 per share3.02FTLFFitLife Brands$63.05M2.78$0.94 per share19.79$3.93 per share4.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$220.66M-$0.84N/AN/AN/AN/A-56.18%-29.61%11/11/2025 (Estimated)CGEMCullinan Therapeutics-$167.38M-$3.23N/AN/AN/AN/A-36.56%-34.82%11/6/2025 (Estimated)DNTHDianthus Therapeutics-$84.97M-$3.25N/AN/AN/A-2,364.56%-34.72%-32.72%11/6/2025 (Estimated)FTLFFitLife Brands$8.98M$0.8422.2516.99N/A12.63%21.70%13.45%N/ALatest FTLF, CGEM, DNTH, and AUTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025AUTLAutolus Therapeutics-$0.24N/AN/AN/A$21.08 millionN/A11/6/2025Q3 2025CGEMCullinan Therapeutics-$0.95N/AN/AN/AN/AN/A11/6/2025Q3 2025DNTHDianthus Therapeutics-$0.88N/AN/AN/A$0.58 millionN/A8/14/2025Q2 2025FTLFFitLife Brands$0.18$0.18N/A$0.18$16.17 million$16.13 million8/12/2025Q2 2025AUTLAutolus Therapeutics-$0.24-$0.18+$0.06-$0.18$12.92 million$13.50 million8/7/2025Q2 2025CGEMCullinan Therapeutics-$0.83-$1.07-$0.24-$1.07N/AN/A8/7/2025Q2 2025DNTHDianthus Therapeutics-$0.86-$0.88-$0.02-$0.88$0.87 million$0.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A8.438.07CGEMCullinan TherapeuticsN/A9.839.83DNTHDianthus TherapeuticsN/A13.1213.12FTLFFitLife Brands0.151.710.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%CGEMCullinan Therapeutics86.31%DNTHDianthus Therapeutics47.53%FTLFFitLife Brands2.32%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%CGEMCullinan Therapeutics7.16%DNTHDianthus Therapeutics8.15%FTLFFitLife Brands61.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableCGEMCullinan Therapeutics3059.07 million54.84 millionOptionableDNTHDianthus Therapeutics8032.19 million29.57 millionOptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableFTLF, CGEM, DNTH, and AUTL HeadlinesRecent News About These CompaniesFitLife Brands' (FTLF) "Hold (C+)" Rating Reiterated at Weiss RatingsOctober 9, 2025 | americanbankingnews.comFitLife Brands (NASDAQ:FTLF) Receives Hold (C+) Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comRecent Price Trend in FitLife Brands (FTLF) is Your Friend, Here's WhyOctober 8, 2025 | zacks.comFitLife Brands (NASDAQ:FTLF) Upgraded by Zacks Research to Strong-Buy RatingOctober 8, 2025 | marketbeat.comFitLife Brands (NASDAQ:FTLF) Will Be Hoping To Turn Its Returns On Capital AroundOctober 4, 2025 | finance.yahoo.comFitLife Brands (NASDAQ:FTLF) Trading Up 0.2% - Still a Buy?September 30, 2025 | marketbeat.comIs FitLife Brands, Inc.'s (NASDAQ:FTLF) Latest Stock Performance A Reflection Of Its Financial Health?September 13, 2025 | finance.yahoo.comJakob York Takes A Bullish Stance, Acquiring FitLife Brands Stock Options Worth $1KSeptember 9, 2025 | benzinga.comEngaging In Insider Activity, Jakob York At FitLife Brands Exercises Options Worth $0September 8, 2025 | benzinga.comFitLife Brands Updates Corporate Presentation StrategyAugust 20, 2025 | msn.comFitLife Brands, Inc. (NASDAQ:FTLF) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | msn.comFitLife Brands price target raised to $25 from $20 at Roth CapitalAugust 15, 2025 | msn.comFitLife Brands Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comFitLife Brands, Inc. (FTLF) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comFitLife Brands Holds 2025 Annual Stockholders MeetingAugust 14, 2025 | msn.comFitLife Brands Reports 5 Percent Q2 DropAugust 14, 2025 | aol.comAFitLife Brands reports Q2 EPS 18c vs. 27c last yearAugust 14, 2025 | msn.comA Peek at FitLife Brands's Future EarningsAugust 13, 2025 | benzinga.comAnalysts Offer Insights on Consumer Goods Companies: Church & Dwight (CHD) and FitLife Brands (FTLF)August 11, 2025 | theglobeandmail.comFitLife Brands Closes Acquisition of Irwin NaturalsAugust 11, 2025 | globenewswire.comFitLife Brands to Acquire Irwin NaturalsAugust 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFTLF, CGEM, DNTH, and AUTL Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.68 -0.04 (-2.33%) Closing price 04:00 PM EasternExtended Trading$1.71 +0.03 (+1.79%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Cullinan Therapeutics NASDAQ:CGEM$8.74 +0.11 (+1.27%) Closing price 04:00 PM EasternExtended Trading$9.07 +0.33 (+3.76%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Dianthus Therapeutics NASDAQ:DNTH$36.00 -0.20 (-0.55%) Closing price 04:00 PM EasternExtended Trading$35.98 -0.02 (-0.06%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.FitLife Brands NASDAQ:FTLF$18.69 -1.34 (-6.69%) Closing price 04:00 PM EasternExtended Trading$18.70 +0.01 (+0.05%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
